Blueprint Medicines (BPMC)
(Real Time Quote from BATS)
$105.60 USD
+0.05 (0.05%)
Updated Jun 17, 2024 10:02 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
BPMC 105.60 +0.05(0.05%)
Will BPMC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPMC
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Other News for BPMC
Blueprint Medicines Shareholders Endorse Key Proposals
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Arcturus Therapeutics (ARCT) and Blueprint Medicines (BPMC)
Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Blueprint Medicines Corporation: A Strong Buy on Robust Clinical Data and Financial Health